the other five were discarded from cross-phenotype genetic association analysis. Surprisingly, most UA and eGFR loci overlap observed, with Xq13.1 being a notable exception. Additionally ...

For decades, treating lung cancer has been like trying to hit a moving target in the dark. Just when doctors think they've found an effective treatment, the cancer adapts and escapes. Now, a team of ...

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...